Otitis Maedia Clinical Trial
Official title:
Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)
Verified date | May 2017 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This post-marketing surveillance study of CLAVAMOX® was designed to collect and assess the
information on proper use, such as safety and efficacy, under actual use conditions,
targeting pediatric Japanese patients with diseases (superficial skin infection, deep skin
infection, lymphangitis, lymphadenitis, chronic pyoderma, pharyngitis, laryngitis,
tonsillitis, acute bronchitis, cystitis, pyelonephritis) other than otitis media.
("CLAVAMOX" is a trademark of the GlaxoSmithKline group of companies.)
Status | Completed |
Enrollment | 363 |
Est. completion date | December 2008 |
Est. primary completion date | December 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 14 Years |
Eligibility |
Inclusion Criteria: - Pediatric subjects with diseases of superficial skin infection, deep skin infection, lymphangitis, lymphadenitis, chronic pyoderma, pharyngitis, laryngitis, tonsillitis, acute bronchitis, cystitis and pyelonephritis Exclusion Criteria: |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The number of incidence of adverse events in Japanese pediatric patients, with diseases other than otitis media, treated with amoxicillin and clavulanate based on prescribing information | 2 months | ||
Primary | Clinical symptoms after treatment with amoxicillin and clavulanate | 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01156701 -
Prophylactic Efficacy of Relenza Against Influenza A and B
|
N/A |